openPR Logo
Press release

How will the Growth Unfold for Leukemia Therapeutics Treatment Market Leaders: Ambit Biosciences Corporation, AriadPharmaceuticals,Inc., Biogen Idec, Inc., Novartis Pharmaceuticals, Bristol-Myers Squibb

07-05-2019 01:12 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Future market insights

How will the Growth Unfold for Leukemia Therapeutics Treatment

Leukemia is defined as a cancer observed in white blood cell (WBC) in our body. White blood cell helps our body to fight against infection caused by harmful pathogen. Bone marrow is the center for the production of RBC (carry oxygen to all part of body), WBC (fight against infection) and platelets (help in blood clotting). Our bone marrow produces abnormal WBC when we are suffering from leukemia. Moreover abnormal WBCs are not able to perform normal functioning or WBC loses its ability to fight against infection. Etiology for leukemia includes artificial ionizing radiation, benzene and petrochemicals, alkylation chemotherapy agents, genetic predisposition and electromagnetic energy.

Major market playerscontributing the global market share of leukemia therapeutics treatment includes Ambit Biosciences Corporation, AriadPharmaceuticals,Inc., Biogen Idec, Inc., Novartis Pharmaceuticals, Bristol-Myers Squibb, Pfizer and others.

Download sample copy of this report:
https://www.futuremarketinsights.com/reports/sample/REP-GB-421

Genetic predisposition and electromagnetic energy is the most common cause of leukemia observed among people. Signs and symptoms of leukemia includes a new lump or swollen gland in neck and arm, frequent nosebleed, pain in the bone, night sweat and frequent fever. Leukemia can be diagnosed by bone marrow tests, platelet count and WBC (white blood cell) differential count test. Leukemia can be treated by blood transfusion, immunotherapy, bone marrow transplantation, radiation therapy and chemotherapy.

Commercially available drug in the market for the treatment of leukemia includes Gleevec, Bosulif, Sprycel, Iclusig and others. Drugs which are in clinical trials expected to launch in the marketwithin next few (3 to 5)years include Bosutinib, Omapro, ga101/rg7159, Vidaza, Dacogen, Midostaurin, Vosaroxin, Quizartinib, Graspa, Marqibo.

The global market for leukemia treatment can be segmented as follows:

Based on the developmental and progression rate Chronic leukemia Acute leukemia
Chronic leukemia is a type of blood cancer caused by uncontrolled growth of the WBC cells in our body. Chronic leukemia is a type of myeloproliferative disease which is characterized by the chromosomal translocation. Patients suffering from chronic leukemia show increased susceptibility to bacterial infections, thrombocytopenia and anemia and may also have enlarged spleen which causes pain on the left side. Incidence rate of chronic leukemia is high in men and is the second most common type of cancer occurring in male adults. Women who are above 50 years in age are expected to suffer from this chronic disease. Treatment for chronic leukemia depends on the phase of the disease that can be chronic, accelerated or the blast phase and the treatment for chronic leukemia includes chemotherapy, stem cell transplants and biologic therapies.

Acute myeloid leukemia develops at a speedy pace and is found in the blood and bone marrow. In the disease process, immature blood cells are present in the bone marrow. Symptoms found in patients due to the disease are flu, loss of weight, body ache, body pain and spots on skin.Treatment for acute leukemia includes chemotherapy, stem cell transplants and biologic therapies.

About 90% of the leukemia cases occur in the middle age and progresses with the aging. Therefore, leukemia therapeutics market is poised to grow with the rise in aging population and increasing incidences of leukemia. Drugs such as Bosulif, Gleevec, Sprycel andIclusigare commercially available for the treatment of leukemia. Gleevec was the first leukemia drug introduced in 2001, since then there has been a revolutionary change in the quality life of patients as compared to the former chemotherapy drugs.Globally the numbers of elderly people, 60 years and above are growing and it is expected that this age group will cross the 2 billion mark in 2050 stated by United Nations Population Division. Hence the leukemia therapeutics market will also grow significantly.However adverse event (cytotoxic) associated with nearly all kinds of leukemia therapeutics treatment might restrict the global market demand of leukemia therapeutics market.

North America dominates the global market for leukemia therapeutics treatment due to high prevalence rate of leukemia (acute, chronic) and extensive technological advancement (diagnosis) in this region. Europe represents the second largest market share due to its large geriatric population base. In addition Asia-Pacific and RoW hold the third and fourth position in the global leukemia therapeutics market respectively due to less prevalence rate of leukemia and lack of proper healthcare facilities in few Asian and African countries.

Buy Now to Get 10% Off and Free Customization as per Requirement:
https://www.futuremarketinsights.com/checkout/421

North America accounted for 62% sales of leukemia drugs in the therapeutics market during 2010 followed by Europe and Asia Pacific. Leukemia therapeutics market will grow significantlyand the total growth will depend on pipeline products and metabolic inhibitors, a tyrosine kinase receptor FLT -3 of Novartis and some other capable molecules, improving the therapeutics market.

Future market insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States

About Us

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release How will the Growth Unfold for Leukemia Therapeutics Treatment Market Leaders: Ambit Biosciences Corporation, AriadPharmaceuticals,Inc., Biogen Idec, Inc., Novartis Pharmaceuticals, Bristol-Myers Squibb here

News-ID: 1797735 • Views:

More Releases from Future market insights

AI in IoT Market Set to Reach USD 172.8 Billion by 2035 with 6.4% CAGR Amid Rising Digital Transformation
AI in IoT Market Set to Reach USD 172.8 Billion by 2035 with 6.4% CAGR Amid Risi …
The AI in IoT market is witnessing rapid expansion as enterprises across industries increasingly integrate artificial intelligence with Internet of Things (IoT) systems. Valued at USD 92.9 billion in 2025, the market is projected to reach USD 172.8 billion by 2035, representing a compound annual growth rate of 6.4%. The integration of AI into IoT infrastructure enables predictive analytics, real-time monitoring, and automated control across multiple applications, transforming how businesses
Catalog Management System Market Poised to Reach USD 4.2 Billion by 2035 with Advanced Technology Integration
Catalog Management System Market Poised to Reach USD 4.2 Billion by 2035 with Ad …
The catalog management system (CMS) market is experiencing steady and strategic growth, with its value projected to rise from USD 1.9 billion in 2025 to USD 4.2 billion by 2035, reflecting a compound annual growth rate (CAGR) of 8.1%. The market expansion is primarily fueled by businesses' growing need for centralized product information, streamlined digital operations, and enhanced customer experiences across increasingly complex sales channels. As e-commerce continues to penetrate global
HIFI Electronics Market Set to Double by 2035, Driven by Premium Audio and Technological Innovation
HIFI Electronics Market Set to Double by 2035, Driven by Premium Audio and Techn …
The global HIFI electronics market is poised for remarkable growth over the next decade, projected to expand from USD 17,243.4 million in 2025 to USD 37,227.2 million by 2035. This impressive growth trajectory, representing an absolute increase of nearly USD 19,983.8 million and a compound annual growth rate (CAGR) of 8%, reflects the rising global appetite for premium audio experiences and high-fidelity sound reproduction across personal and professional applications. The expansion
Interrogation Table Market to Reach USD 435.7 Million by 2035, Driven by Security Infrastructure Expansion
Interrogation Table Market to Reach USD 435.7 Million by 2035, Driven by Securit …
The global interrogation table market, valued at USD 321.1 million in 2025, is set to grow steadily to USD 435.7 million by 2035, registering a moderate CAGR of 3.1%. This trajectory reflects a market gradually approaching maturity, where incremental demand for specialized security furniture outweighs rapid expansion. The early stage from 2025 to 2028 is expected to see modest increases in annual revenues, primarily linked to new infrastructure development across

All 5 Releases


More Releases for Leukemia

The Impact Of Increasing Leukemia Prevalence On The Leukemia Therapeutics Market …
The Leukemia Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Leukemia Therapeutics Market Size During the Forecast Period? In recent times, the market size for leukemia therapeutics has seen robust growth. It is projected to increase from $17.57 billion in 2024
Leukemia Therapeutics Market - Revolutionizing Leukemia Care: Cutting-Edge Thera …
Newark, New Castle, USA: The "Leukemia Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Leukemia Therapeutics Market: https://www.growthplusreports.com/report/leukemia-therapeutics-market/7759 This latest report researches the industry structure, sales, revenue,
Acute Lymphoblastic Leukemia Therapeutics Market Size, Acute Lymphoblastic Leuke …
Acute Lymphoblastic Leukemia Therapeutics Market Dynamics are clarified by an in-depth review of facts on current and emerging trends. To understand a resource, the paper uses Porter's five forces to examine the importance of numerous qualities such as understanding of suppliers and customers, dangers provided by various agents, competitive strength, and promising new businesses. precious. Furthermore, the study covers numerous firms' Acute Lymphoblastic Leukemia Therapeutics research data, benefit, gross margin,
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, T …
Orbisreserach.Com Adds “H1 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Market Pipeline Review 2017 Trend Analysis Report Report” To Its Research Database Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2017, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline landscape. Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical T …
ReportsWorldwide has announced the addition of a new report title Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Tri …
ReportsWorldwide has announced the addition of a new report title Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) clinical trials scenario. This report provides top line data relating to